Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: Systemic therapy and therapeutic individualization

Joseph A. Sparano, Gabriel N. Hortobagyi, Julie R. Gralow, Edith A. Perez, Robert L. Comis

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Over 9,000 women with breast cancer are enrolled annually on clinical trials sponsored by the National Cancer Institute (NCI), accounting for about one-third of all patients enrolled on NCI-sponsored trials. Thousands are also enrolled on pharmaceutical-sponsored studies. Although breast cancer mortality rates have recently declined for the first time in part due to systemic therapeutic advances, coordinated efforts will be necessary to maintain this trend. The Coalition of Cancer Cooperative Groups convened the Scientific Leadership Council in breast cancer (BC), an expert panel, to identify priorities for future research and current trials with greatest practice-changing potential. Panelists formed a consensus on research priorities for chemoprevention, development and application of molecular markers for predicting therapeutic benefit and toxicity, intermediate markers predictive of therapeutic effect, pathogenesis-based therapeutic approaches, utilization of adaptive designs requiring fewer patients to achieve objectives, special and minority populations, and effects of BC and treatment on patients and families. Panelists identified 13 ongoing studies as High Priority and identified gaps in the current trial portfolio. We propose priorities for current and future clinical breast cancer research evaluating systemic therapies that may serve to improve the efficiency of clinical trials, identify individuals most likely to derive therapeutic benefit, and prioritize therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)511-527
Number of pages17
JournalBreast Cancer Research and Treatment
Volume119
Issue number3
DOIs
StatePublished - Feb 2010

Fingerprint

Breast Neoplasms
Research
Neoplasms
National Cancer Institute (U.S.)
Therapeutics
Clinical Trials
Chemoprevention
Therapeutic Uses
Consensus
Mortality
Pharmaceutical Preparations
Population

Keywords

  • Breast cancer
  • Chemotherapy
  • Endocrine therapy
  • Therapeutic individualization

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council : Systemic therapy and therapeutic individualization. / Sparano, Joseph A.; Hortobagyi, Gabriel N.; Gralow, Julie R.; Perez, Edith A.; Comis, Robert L.

In: Breast Cancer Research and Treatment, Vol. 119, No. 3, 02.2010, p. 511-527.

Research output: Contribution to journalArticle

@article{9df1b60c23814b289868b7200a109ac9,
title = "Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: Systemic therapy and therapeutic individualization",
abstract = "Over 9,000 women with breast cancer are enrolled annually on clinical trials sponsored by the National Cancer Institute (NCI), accounting for about one-third of all patients enrolled on NCI-sponsored trials. Thousands are also enrolled on pharmaceutical-sponsored studies. Although breast cancer mortality rates have recently declined for the first time in part due to systemic therapeutic advances, coordinated efforts will be necessary to maintain this trend. The Coalition of Cancer Cooperative Groups convened the Scientific Leadership Council in breast cancer (BC), an expert panel, to identify priorities for future research and current trials with greatest practice-changing potential. Panelists formed a consensus on research priorities for chemoprevention, development and application of molecular markers for predicting therapeutic benefit and toxicity, intermediate markers predictive of therapeutic effect, pathogenesis-based therapeutic approaches, utilization of adaptive designs requiring fewer patients to achieve objectives, special and minority populations, and effects of BC and treatment on patients and families. Panelists identified 13 ongoing studies as High Priority and identified gaps in the current trial portfolio. We propose priorities for current and future clinical breast cancer research evaluating systemic therapies that may serve to improve the efficiency of clinical trials, identify individuals most likely to derive therapeutic benefit, and prioritize therapeutic strategies.",
keywords = "Breast cancer, Chemotherapy, Endocrine therapy, Therapeutic individualization",
author = "Sparano, {Joseph A.} and Hortobagyi, {Gabriel N.} and Gralow, {Julie R.} and Perez, {Edith A.} and Comis, {Robert L.}",
year = "2010",
month = "2",
doi = "10.1007/s10549-009-0433-y",
language = "English (US)",
volume = "119",
pages = "511--527",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council

T2 - Systemic therapy and therapeutic individualization

AU - Sparano, Joseph A.

AU - Hortobagyi, Gabriel N.

AU - Gralow, Julie R.

AU - Perez, Edith A.

AU - Comis, Robert L.

PY - 2010/2

Y1 - 2010/2

N2 - Over 9,000 women with breast cancer are enrolled annually on clinical trials sponsored by the National Cancer Institute (NCI), accounting for about one-third of all patients enrolled on NCI-sponsored trials. Thousands are also enrolled on pharmaceutical-sponsored studies. Although breast cancer mortality rates have recently declined for the first time in part due to systemic therapeutic advances, coordinated efforts will be necessary to maintain this trend. The Coalition of Cancer Cooperative Groups convened the Scientific Leadership Council in breast cancer (BC), an expert panel, to identify priorities for future research and current trials with greatest practice-changing potential. Panelists formed a consensus on research priorities for chemoprevention, development and application of molecular markers for predicting therapeutic benefit and toxicity, intermediate markers predictive of therapeutic effect, pathogenesis-based therapeutic approaches, utilization of adaptive designs requiring fewer patients to achieve objectives, special and minority populations, and effects of BC and treatment on patients and families. Panelists identified 13 ongoing studies as High Priority and identified gaps in the current trial portfolio. We propose priorities for current and future clinical breast cancer research evaluating systemic therapies that may serve to improve the efficiency of clinical trials, identify individuals most likely to derive therapeutic benefit, and prioritize therapeutic strategies.

AB - Over 9,000 women with breast cancer are enrolled annually on clinical trials sponsored by the National Cancer Institute (NCI), accounting for about one-third of all patients enrolled on NCI-sponsored trials. Thousands are also enrolled on pharmaceutical-sponsored studies. Although breast cancer mortality rates have recently declined for the first time in part due to systemic therapeutic advances, coordinated efforts will be necessary to maintain this trend. The Coalition of Cancer Cooperative Groups convened the Scientific Leadership Council in breast cancer (BC), an expert panel, to identify priorities for future research and current trials with greatest practice-changing potential. Panelists formed a consensus on research priorities for chemoprevention, development and application of molecular markers for predicting therapeutic benefit and toxicity, intermediate markers predictive of therapeutic effect, pathogenesis-based therapeutic approaches, utilization of adaptive designs requiring fewer patients to achieve objectives, special and minority populations, and effects of BC and treatment on patients and families. Panelists identified 13 ongoing studies as High Priority and identified gaps in the current trial portfolio. We propose priorities for current and future clinical breast cancer research evaluating systemic therapies that may serve to improve the efficiency of clinical trials, identify individuals most likely to derive therapeutic benefit, and prioritize therapeutic strategies.

KW - Breast cancer

KW - Chemotherapy

KW - Endocrine therapy

KW - Therapeutic individualization

UR - http://www.scopus.com/inward/record.url?scp=74849135474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74849135474&partnerID=8YFLogxK

U2 - 10.1007/s10549-009-0433-y

DO - 10.1007/s10549-009-0433-y

M3 - Article

C2 - 19526354

AN - SCOPUS:74849135474

VL - 119

SP - 511

EP - 527

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -